Hapvida Participacoes e Investimentos (HAPV3) Q4 2025 earnings summary

Executive summary

• Q4 2025 results missed expectations due to higher MLR, weak member growth, and operational challenges, especially in less mature and competitive regions.

• Net revenue for 4Q25 reached R$7.9 billion, up 1.8% sequentially and 5.9% year-over-year; full-year 2025 revenue was R$30.9 billion.

• Adjusted EBITDA for 4Q25 was R$714 million (9.0% margin), down 4.4% sequentially and 32.8% year-over-year; adjusted net income was R$181 million.

• CEO transition is underway, with Luccas Adib set to take over, emphasizing continuity and renewal in execution.

• Integrated model and transformation agenda focus on operational discipline, governance, and digital transformation.

Financial highlights

• Q4 2025 saw a net loss of 140,000 health beneficiaries, with gross additions over 600,000 but high churn; dental beneficiaries increased by 23,000 sequentially.

• Cash MLR was 75.5%, up 0.2 p.p. quarter-on-quarter and 4.5 p.p. year-over-year, driven by higher utilization and fixed costs from new units.

• Adjusted EBITDA was R$714 million, including R$158 million in one-off events; excluding these, EBITDA was R$556 million.

• Adjusted net income for 4Q25 was R$181 million (2.3% margin), but only R$76.4 million (1.0% margin) excluding one-offs.

• CapEx for Q4 was R$419 million; 2026 CapEx guidance is R$600–700 million, including intangibles and fixed assets.

• Net debt increased to R$5.18 billion at 4Q25, with leverage at 1.32x EBITDA; free cash at year-end was R$8.19 billion.

Outlook and guidance

• 2026 priorities: rational growth in lagging markets, margin recovery via higher own network occupancy and care management, and tighter capital discipline.

• No significant new unit openings planned for 2026; focus on optimizing existing assets and possibly shutting down underperforming units.

• Gradual normalization of healthcare indicators expected in 2026, with sequential MLR improvement as utilization normalizes.

• CapEx to be stricter, with focus on ROI and selective investments.